SEC Comment Letter 0000000000-23-008900 to Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc.
Date: Aug. 15, 2023 · CIK: 0001517681 · Accession: 0000000000-23-008900
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273953
Letter
United States securities and exchange commission logo August 15, 2023 James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. 302, 6 Butler Street Camberwell, VIC 3124 Australia Re:Propanc Biopharma, Inc. Registration Statement on Form S-1 Filed August 11, 2023 File No. 333-273953 Dear James Nathanielsz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael DeDonato, Esq.
Show Raw Text
United States securities and exchange commission logo
August 15, 2023
James Nathanielsz
Chief Executive Officer
Propanc Biopharma, Inc.
302, 6 Butler Street
Camberwell, VIC 3124 Australia
Re:Propanc Biopharma, Inc.
Registration Statement on Form S-1
Filed August 11, 2023
File No. 333-273953
Dear James Nathanielsz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael DeDonato, Esq.